Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 275

Posts Tagged ‘psoriasis’

Boehringer Ingelheim’s novel antibody shows potential to transform treatment of rare form of psoriasis

Posted by fidest press agency su domenica, 10 marzo 2019

The New England Journal of Medicine (NEJM) today published new data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved symptoms of generalised pustular psoriasis (GPP), a rare form of psoriasis.
BI 655130 is a monoclonal antibody that blocks the action of the interleukin-36 receptor (IL-36R), a signalling pathway within the immune system that may play a role in many inflammatory diseases.The newly published clinical data, which were also presented at the recent American Academy of Dermatology (AAD) annual meeting in Washington D.C.,2 indicate that BI 655130 rapidly improved symptoms in seven patients with GPP, who were experiencing acute moderate or severe disease flares.1 Five of seven patients in the 20-week, Phase I clinical trial achieved clear or almost clear skin within the first week, following a single dose of treatment, and all patients achieved this outcome after four weeks.1 The average improvement in patients’ skin symptoms was close to 80 per cent at week four and was maintained until the end of the study (week 20). The rare skin disease, GPP, is a chronic condition that is distinct from the more common condition, plaque psoriasis.3 It has a considerable impact on people’s quality of life. The skin becomes red and erupts into numerous blisters of non-infectious pus (pustules), covering wide areas of the body.4,5,6 People who develop GPP may experience an abrupt onset of fever, chills and painful skin lesions.4,5,6 GPP may be associated with life-threatening organ failure and infectious complications, and, therefore, should be considered a medical emergency.7 Available treatment options for GPP are extremely limited and lack profound and persistent efficacy. Therefore, there is a strong need for new treatment options for GPP with rapid, strong and persistent efficacy.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Psoriasis Treatments

Posted by fidest press agency su venerdì, 22 giugno 2018

A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis (PsO) every year in the United States, affecting 2.2% of the population. Approximately 80% of those affected have mild-to-moderate psoriasis, while 20% have moderate-to-severe psoriasis, which is often treated with immunology drugs. These drugs command a high price, but there may be hope for better options in the future.People with psoriasis suffer from the overproduction of skin cells, which causes the redness and inflammation typically found on elbows, knees, or the scalp. The disease is usually associated with other serious health conditions, often involving the immune system. Crohn’s disease and ulcerative colitis are some examples, both of which can be up to 7 times more prevalent in psoriasis patients.Psoriasis patients have a number of treatment options, ranging from non-steroidal anti-inflammatory drugs for initial treatment to biologics, which are more often used in moderate-to-severe forms of the disease. The PsO market is dominated by drugs such as Humira®, Enbrel®, Remicade® and Stelara®, but more competition is coming soon from biosimilars as patents begin to expire.Research by iData shows that the average annual drug cost per patient in the U.S. is over $60,000. Stelara® and Humira® are the most-prescribed immunology drugs for psoriasis treatment, due to their high efficacy, and are clearly benefiting from the lack of competition, which enables them to sell at these prices.The U.S. psoriasis market is valued at almost $5 billion, growing year over year. According to this latest study, the PsO market is expected to reach $6.33 billion by 2023. This market growth is driven by the high cost of the biologics, unmet needs in the psoriasis space, and the efficacy of anti-TNF biologics. “Despite this trend, biologics are seeing a lower growth rate as a direct result of competition from the immunology biosimilar market, which will experience a compound annual growth rate exceeding 30% over the forecast period,” says Dr. Kamran Zamanian, President and CEO of iData Research.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , | Leave a Comment »